Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO

Only five months after securing a $100 million IPO, Boundless Bio is already laying off some employees as the precision oncology company grapples with low enrollment for a trial of its lead drug.